Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최한곤 | - |
dc.date.accessioned | 2023-06-23T02:15:44Z | - |
dc.date.available | 2023-06-23T02:15:44Z | - |
dc.date.issued | 2016-03 | - |
dc.identifier.citation | JOURNAL OF CONTROLLED RELEASE, v. 225, Page. 301.0-313.0 | - |
dc.identifier.issn | 0168-3659;1873-4995 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0168365916300426?via%3Dihub | en_US |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/182326 | - |
dc.description.abstract | Albumin nanoparticles have been increasingly viewed as an effective way of delivering chemotherapeutics to solid tumors. Here, we report the one-pot development of a unique prototype of doxorubicin-loaded nanoparticles (NPs) made of naive albumin (HSA) plus cationic- (c-HSA) or mannose-modified-albumin (m-HSA), with the goal of traversing the blood-brain barrier and targeting brain tumors. c-HSA was synthesized by conjugating ethylenediamine to naive HSA. Then, m-HSA was derivatized using mannopyranoside via a thiol-maleimide reaction. The c/m-HSA NPs were prepared using a mixture solution of c-and m-HSAs in deionized water and doxorubicin in ethanol/chloroform in the same pot using a high-pressure homogenizer. The c/m-HSA NPs were spherical and well-dispersed, with a particle size of 90.5 +/- 3.1 nm and zeta-potential of -12.0 +/- 0.3 mV at c- and m-HSA feed ratios of 5% and 10%, respectively. The c/m-HSA NPs displayed good stability over 3 days based on particle size and a linear gradual doxorubicin release over 2 days. Specifically, the inhibitory concentration (IC50; 0.5 +/- 0.02 mu g/ml) of c/m-HSA NPs was > 2.2-15.6 fold lower than those of doxorubicin or the other HSA NPs. Moreover, among HSA NPs, c/m-HSA NPs exhibited the most prominent performances in transport across the bEnd. 3 cell monolayer and uptake in bEnd. 3 cells as well as U87MG glioblastoma cells and spheroids. Furthermore, c/m-HSA NPs were localized to a greater extent in brain glioma compared to naive HSA NPs. Orthotopic glioma-bearing mice treated with c/m-HSA NPs displayed significantly smaller tumors than the mice treated with saline, doxorubicin or HSA NPs. This improved anti-glioma efficacy seemed to be due to the dual-enhanced system of dual cationic absorptive transcytosis and glucose-transport by the combined use of c-and m-HSAs. The c/m-HSA NPs have potential as a novel anti-brain cancer agent with good targetability. (C) 2016 Elsevier B.V. All rights reserved. | - |
dc.description.sponsorship | Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea HI15C2221 | - |
dc.language | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.subject | Albumin nanoparticles | - |
dc.subject | Blood-brain barrier | - |
dc.subject | Doxorubicin | - |
dc.subject | Brain tumor | - |
dc.subject | Targeting | - |
dc.title | Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors | - |
dc.type | Article | - |
dc.relation.volume | 225 | - |
dc.identifier.doi | 10.1016/j.jconrel.2016.01.046 | - |
dc.relation.page | 301.0-313.0 | - |
dc.relation.journal | JOURNAL OF CONTROLLED RELEASE | - |
dc.contributor.googleauthor | Byeon, Hyeong Jun | - |
dc.contributor.googleauthor | Thao, Le Quang | - |
dc.contributor.googleauthor | Lee, Seunghyun | - |
dc.contributor.googleauthor | Min, Sun Young | - |
dc.contributor.googleauthor | Lee, Eun Seong | - |
dc.contributor.googleauthor | Shin, Beom Soo | - |
dc.contributor.googleauthor | Choi, Han-Gon | - |
dc.contributor.googleauthor | Youn, Yu Seok | - |
dc.sector.campus | E | - |
dc.sector.daehak | 약학대학 | - |
dc.sector.department | 약학과 | - |
dc.identifier.pid | hangon | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.